A multidisciplinary intervention to reduce central line-associated bloodstream infection in pediatrics and neonatal intensive care units

Affiliations


Abstract

Background: To date, central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infections in high-risk neonates and children. These infections are associated with significantly longer hospital stays, increased health care cost, and mortality in the health care systems. Application of evidence-based preventive interventions has proven to decrease CLABSI rate. The purpose of this study is to reduce the undesired relative high CLABSI rate through the adoption of standardized quality improvement interventions.

Methods: and Methods: The study employed a pre-post-intervention design. Phase one is a retrospective calculation of 12 months of surveillance period as a baseline. Phase 2 establishes a multidisciplinary quality improvement intervention, which includes the formation of a dedicated central line insertion team, provision of central line kit at the bedside, training and educating the team, and selecting bundle checklist. In the third phase, we performed auditing and calculating the checklist compliance and monthly feedback for 12 consecutive post-intervention months. During phase 1 and 3, we calculated the following measures; CLABSI per 1000 catheter-days, duration of central line use, and device utilization ratio.

Results: During the post-intervention phase the CLABSI rate significantly reduced by 59.5% from 7.5 to 3.0 per 1000 central line day, and the duration of use of the central line decreased from 21.3 ± 9.9 to 11.0 ± 3.2 days (P < 0.05).

Conclusion: Implementation of quality improvement multidisciplinary intervention; central line insertion and maintenance care bundle, dedicated IV team, education and feedback effectively reduced the rate of CLABSI within our pediatrics and neonatal ICUs.

Keywords: bundle of care; infection control; intensivist; intervention.

Conflict of interest statement

Declaration of competing interest None declared.


Similar articles

How to minimize central line-associated bloodstream infections in a neonatal intensive care unit: a quality improvement intervention based on a retrospective analysis and the adoption of an evidence-based bundle.

Bierlaire S, Danhaive O, Carkeek K, Piersigilli F.Eur J Pediatr. 2021 Feb;180(2):449-460. doi: 10.1007/s00431-020-03844-9. Epub 2020 Oct 20.PMID: 33083900

Reducing central line-associated bloodstream infections in North Carolina NICUs.

Fisher D, Cochran KM, Provost LP, Patterson J, Bristol T, Metzguer K, Smith B, Testoni D, McCaffrey MJ.Pediatrics. 2013 Dec;132(6):e1664-71. doi: 10.1542/peds.2013-2000. Epub 2013 Nov 18.PMID: 24249819 Clinical Trial.

Utilizing a line maintenance team to reduce central-line-associated bloodstream infections in a neonatal intensive care unit.

Holzmann-Pazgal G, Kubanda A, Davis K, Khan AM, Brumley K, Denson SE.J Perinatol. 2012 Apr;32(4):281-6. doi: 10.1038/jp.2011.91. Epub 2011 Oct 20.PMID: 22011970

The effect of the multimodal intervention including an automatic notification of catheter days on reducing central line-related bloodstream infection: a retrospective, observational, quasi-experimental study.

Bae S, Kim Y, Chang HH, Kim S, Kim HJ, Jeon H, Cho J, Lee J, Chae H, Han G, Kim SW.BMC Infect Dis. 2022 Jul 8;22(1):604. doi: 10.1186/s12879-022-07588-9.PMID: 35804323 Free PMC article. Review.

Rapid cycle development of a multifactorial intervention achieved sustained reductions in central line-associated bloodstream infections in haematology oncology units at a children's hospital: a time series analysis.

Dandoy CE, Hausfeld J, Flesch L, Hawkins D, Demmel K, Best D, Osterkamp E, Bracke T, Nagarajan R, Jodele S, Holt J, Giaccone MJ, Davies SM, Kotagal U, Simmons J.BMJ Qual Saf. 2016 Aug;25(8):633-43. doi: 10.1136/bmjqs-2015-004450. Epub 2015 Nov 25.PMID: 26608456 Review.


Cited by

The OBTAINS study: A nationwide cross-sectional survey on the implementation of extended or continuous infusion of β-lactams and vancomycin among neonatal sepsis patients in China.

Zhou P, Cheng Y, Cao G, Xing Y, Zhai S, Tong X, Yang K.Front Pharmacol. 2022 Oct 10;13:1001924. doi: 10.3389/fphar.2022.1001924. eCollection 2022.PMID: 36299905 Free PMC article.


KMEL References